Buy Lynkuet Online

Other known brand names

Lynkuet. The active ingredient is elinzanetant. There are no other currently licensed brand names for elinzanetant in the UK.

About Lynkuet

Lynkuet contains the active ingredient elinzanetant, a non-hormonal medicine developed by Bayer AG for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. It is the world’s first dual neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist to be licensed for this indication. Lynkuet is taken once daily at bedtime as a 120 mg oral dose (two 60 mg soft capsules). It was first approved in the UK by the MHRA in July 2025 and is currently available on private prescription only.

Lynkuet is commonly prescribed to treat moderate to severe hot flushes and night sweats (collectively known as vasomotor symptoms), a condition in which declining oestrogen levels during menopause cause the brain’s thermoregulatory centre (the hypothalamus) to become hyper-reactive to small temperature changes. Elinzanetant works by blocking both NK1 and NK3 receptors on specialised hypothalamic nerve cells called KNDy neurones (kisspeptin/neurokinin B/dynorphin neurones). By inhibiting signalling through both receptors, it normalises the overactive neural pathway that triggers hot flushes and disrupts sleep, reducing both the frequency and severity of vasomotor events.

Lynkuet is not a hormonal treatment and does not function as a contraceptive. It is a prescription-only medicine and may be recommended when HRT is medically unsuitable or not desired, or as a treatment for menopausal vasomotor symptoms in women receiving adjuvant endocrine therapy for breast cancer (in the EU).

NowPatient offers Lynkuet as a treatment for moderate to severe menopausal vasomotor symptoms following an online consultation with a prescriber.

Key facts of Lynkuet

• For the treatment of moderate to severe vasomotor symptoms (hot flushes and night sweats) associated with menopause
• Lynkuet has some common side effects which include fatigue, somnolence (drowsiness), headache, diarrhoea, muscle spasms, and dizziness
• It can interact with strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, clarithromycin, ritonavir) — co-administration is contraindicated. Dose reduction to one capsule (60 mg) is required with moderate CYP3A4 inhibitors (e.g. erythromycin, diltiazem, verapamil, fluconazole). Grapefruit and grapefruit juice must also be avoided. If you’re not sure if it is safe to use with other treatments, discuss this with the prescribing clinician
• Lynkuet is not a contraceptive and does not contain hormones
• Women of child-bearing potential must use effective non-hormonal contraception during treatment
• Liver function tests (ALT, AST, ALP, bilirubin) must be performed before starting treatment and repeated at three months
• You should not start Lynkuet if your liver enzymes (ALT or AST) are ≥2 times the upper limit of normal, or if total bilirubin is ≥2 times the upper limit of normal
• Lynkuet may increase skin sensitivity to sunlight (photosensitivity) — use sunscreen and protective clothing when outdoors during treatment

Who is Lynkuet suitable for?

Lynkuet is suitable for adults, specifically women aged 40 years and over, who experience moderate to severe vasomotor symptoms (hot flushes and night sweats) associated with menopause. It is of particular relevance to women for whom hormone replacement therapy (HRT) is medically contraindicated, not well tolerated, or personally not desired. It is also indicated in the EU for women experiencing vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer. Clinical trial data support its use in postmenopausal women aged 40 to 65 years.

Who is Lynkuet not suitable for?

Lynkuet may not be suitable for some people. To make sure it’s safe for you, speak to the NowPatient prescribing clinician before using Lynkuet if you:

• Are pregnant, suspect you may be pregnant, or are planning to become pregnant — Lynkuet is contraindicated in pregnancy and may cause pregnancy loss or stillbirth
• Are breastfeeding — it is unknown whether elinzanetant passes into breast milk
• Have moderate to severe hepatic impairment (liver disease) — Lynkuet is not recommended
• Have a history of seizures or epilepsy
• Are taking strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, clarithromycin, ritonavir) — co-administration is contraindicated
• Have significantly elevated liver enzymes (ALT or AST ≥2x upper limit of normal) or elevated total bilirubin (≥2x upper limit of normal) before starting treatment
• Are hypersensitive (allergic) to elinzanetant or any of the excipients in the capsule
• Are currently using hormone replacement therapy — combined use has not been studied and is not recommended
• Are using hormonal contraceptives — non-hormonal contraception is recommended during treatment

How and where to get Lynkuet?

You can buy Lynkuet safely and securely from NowPatient. You can start a consultation today for free and if you qualify for treatment, you only pay for the cost of the medication. Delivery is made to your home or office from our registered pharmacy.

Our service is certified, safe and effective, and we only ever treat conditions. If you book a consultation with a prescribing clinician for the treatment of moderate to severe menopausal vasomotor symptoms, you can discuss if Lynkuet is a suitable treatment option for you.

At the end of the consultation, the clinician will decide if a treatment plan is suitable for you. If it is, the clinician will issue you with a prescription which can then be ordered, paid for and delivered directly to your chosen address by NowPatient.

Dosage and strength for Lynkuet for menopausal vasomotor symptoms

Lynkuet comes as 60 mg soft capsules (opaque red, oblong, marked “EZN60”). The recommended dose is 120 mg (two 60 mg capsules) taken orally once daily at bedtime, with or without food. The capsules should be swallowed whole with water and must not be cut, crushed, or chewed.

A reduced dose of one 60 mg capsule once daily is required if you are taking a moderate CYP3A4 inhibitor (such as erythromycin, diltiazem, verapamil, or fluconazole). If only one capsule is required per dose, partially peel back the blister foil to expose one capsule only, and leave the remaining capsule sealed until the next dose.

If you miss a bedtime dose, take your next scheduled dose the following evening. Do not double up or take more than two capsules in one day.

What happens if you use too much Lynkuet?

If you take more than the prescribed dose, you should not expect faster results and may experience an increase in side effects, particularly drowsiness, dizziness, headache, and fatigue.

If you have taken too much or experience significant discomfort, stop taking Lynkuet and speak to your doctor or reach out to one of our prescribing clinicians. In a serious overdose situation, contact NHS 111 or seek emergency medical attention.

What are the side effects of Lynkuet?

Side effects of Lynkuet are split into common and serious.

Common side effects include:

• Fatigue (tiredness)
• Somnolence (drowsiness) — this is why Lynkuet is taken at bedtime
• Headache
• Diarrhoea
• Muscle spasms
• Dizziness
• Photosensitivity (increased sensitivity of skin to sunlight)

Serious side effects include:

• Liver injury — elevations of liver enzymes (ALT, AST) have been observed during treatment; liver function must be monitored before treatment and at three months. Contact your prescriber if you experience yellowing of the skin or eyes (jaundice), dark urine, unexplained nausea, or upper abdominal pain
• Seizures — Lynkuet is not recommended for women with a history of epilepsy or seizure disorders; seek immediate medical attention if you experience a seizure
• Nervous system effects including presyncope (near-fainting), vertigo, and falls, particularly following the initial dose
• Pregnancy loss or stillbirth if taken during pregnancy — Lynkuet must be stopped immediately if pregnancy occurs and medical advice sought

If you experience any serious side effects, you should contact NHS 111.

If you experience a serious allergic reaction with the signs shown below, you should contact emergency services on 999:

• Your lips, mouth, throat or tongue suddenly become swollen
• You’re breathing very fast or struggling to breathe (you may become very wheezy or feel like you’re choking or gasping for air)
• Your throat feels tight or you’re struggling to swallow
• Your skin, tongue or lips turn blue, grey or pale (if you have black or brown skin, this may be easier to see on the palms of your hands or soles of your feet)
• You suddenly become very confused, drowsy or dizzy
• Someone faints and cannot be woken up

Always report adverse effects to the MHRA Yellow Card reporting system. You can read more about this here: How and where do I report side effects of my medication?

Information about using Lynkuet with other medications

Elinzanetant is primarily metabolised by the CYP3A4 enzyme. The following drug interactions are clinically significant:

• Strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, clarithromycin, ritonavir, cobicistat): Contraindicated — these drugs significantly increase elinzanetant exposure and must not be used together
• Moderate CYP3A4 inhibitors (e.g. erythromycin, diltiazem, verapamil, fluconazole): Reduce Lynkuet dose to one 60 mg capsule once daily
• CYP3A4 substrates with a narrow therapeutic window (e.g. ciclosporin, fentanyl, tacrolimus): Lynkuet is a weak CYP3A4 inhibitor and may increase exposure of these drugs; follow guidance in their prescribing information
• Grapefruit and grapefruit juice: Must be avoided completely during treatment, as they act like CYP3A4 inhibitors and raise elinzanetant levels
• Hormonal contraceptives: Lynkuet’s interaction with hormonal contraceptives has not been fully studied; non-hormonal contraception (e.g. condoms, copper IUD) is recommended for women of child-bearing potential during treatment

Let your prescribing clinician know about all medications, supplements, and herbal products you are taking before starting Lynkuet.

Why might Lynkuet not work for vasomotor symptoms?

Lynkuet may take a number of weeks to produce its full effect. In clinical trials, significant reductions in hot flush frequency were observed as early as week 1, with continued improvement through week 12 and beyond. If, after 12 weeks, your symptoms have not meaningfully improved, you should speak with your healthcare provider for further advice.

Lynkuet is specifically effective for hot flushes and night sweats. It does not treat other menopausal symptoms such as vaginal dryness, mood changes, brain fog, or reduced libido. If these are your primary concerns, discuss alternative or additional treatments with your prescribing clinician.

Can Lynkuet be used long term?

Lynkuet can be used as long as your clinician recommends it. Clinical trial data, including the 52-week OASIS-3 study, support its continued efficacy and tolerability over at least one year. Liver function should continue to be monitored during long-term use. Your prescribing clinician will review your treatment periodically to assess whether it remains appropriate.

How to store Lynkuet

• Keep Lynkuet out of the sight and reach of children
• Do not use this medicine after the expiry date shown on the carton and blister pack (marked as “EXP”). The expiry date refers to the last day of that month
• Store at room temperature, between 15°C and 30°C (68°F–86°F). Store in a cool, dry place
• Keep capsules in the original blister packaging until you are ready to take them. Only remove a capsule from the blister pack immediately before use
• If your dose is one capsule, peel back the foil only enough to access one capsule, leaving the second capsule sealed until the following evening
• Do not dispose of unused Lynkuet capsules in wastewater or household waste. Ask your pharmacist how to properly dispose of medicines you no longer use. These steps help protect the environment

Is there a herbal Lynkuet?

No. Herbal Lynkuet does not exist. If you have been marketed such a product, it may be counterfeit or unsafe.

Should I avoid any particular food or drink when using Lynkuet?

You can eat and drink normally while using Lynkuet. However, you must completely avoid grapefruit and grapefruit juice throughout your treatment, as these significantly increase elinzanetant levels in the blood and may increase the risk of side effects.

You should also limit sun exposure and use sunscreen (SPF 30 or higher) with protective clothing when outdoors, as Lynkuet may increase your skin’s sensitivity to ultraviolet (UV) light.

What lifestyle changes can I make to help with menopausal hot flushes and night sweats?

There are several lifestyle changes that may improve your vasomotor symptoms:

• Keep your environment cool: Use a fan or air conditioning, keep bedroom windows open at night, and use lightweight, breathable bedding
• Dress in layers: Wear loose-fitting, moisture-wicking fabrics that are easy to remove when a flush occurs
• Identify and avoid triggers: Common triggers include spicy foods, caffeine, alcohol, hot drinks, and stress — keeping a symptom diary can help identify your personal triggers
• Regular exercise: Moderate aerobic exercise (e.g. walking, swimming, cycling) can help reduce both the frequency and severity of hot flushes and improve sleep quality
• Maintain a healthy weight: Excess body weight is associated with more severe vasomotor symptoms
• Manage stress: Relaxation techniques such as yoga, mindfulness, and controlled breathing exercises (paced respiration) have been shown to reduce hot flush frequency in some women
• Quit smoking: Smoking is associated with earlier menopause and more severe vasomotor symptoms
• Limit alcohol: Alcohol can trigger or worsen hot flushes and disrupt sleep

Alternatives to Lynkuet

Alternatives for the treatment of menopausal vasomotor symptoms include:

Hormonal treatments (HRT) 

• Evorel patches (estradiol)
• Evorel Conti patches (estradiol + norethisterone)
• Estradot patches (estradiol)
• Estradiol (vaginal pessaries for local symptoms)

Non-hormonal treatments 

• Veoza (fezolinetant) — NK3 receptor antagonist, now available on the NHS in England when HRT is unsuitable

Your prescriber will help decide which option is most suitable for your symptoms, medical history, and personal preferences.